Meet UNIVERCELLS at the Single-Use Technologies III! Alex Chatel will present how Univercells is able to optimize #SingleUse technologies to develop an #affordable, low-footprint platform for the production of #viral#vaccines
UNIVERCELLS formally announces the appointment of Pierre A. MORGON PharmD LL.M MBA as a member of the Board of Directors.Dr. Pierre Morgon brings his notable experience and extensive industry knowledge to reinforce Univercells’ business strategy and accelerate the worldwide dissemination of its #biomanufacturing solutions https://goo.gl/QV4bR2
UNIVERCELLS is happy to welcome on board four new members to the team! They will reinforce the #analytical, #legal and #bioprocess development departments. Welcome Barbara Bolle, Thomas Bouckenooghe,PhD, Jessica Lindmark and Mathieu Spicy!
#Measles#virus is spread in the air through coughing or sneezing and can lead to severe complications. According to @World Health Organization, #measles cases have reached the highest this decade in Europe, with more than 41,000 children and adults infected in the first 6 months of 2018 and 37 deaths (compared to 23,927 in 2017 and 5,237 in 2016). To prevent transmission of this highly contagious virus it is crucial to have #vaccination rates of at least 95 percent. Read more about the re-emergence of measles in Europe and WHO’s efforts to reach this 95% immunization threshold: https://goo.gl/XuqCiv
On September 5, Renaud JACQUEMART from our partner Batavia Biosciences, will present at the BioProcess International our breakthrough vaccine manufacturing platform that aims to deliver 40-60M doses of Sabin inactivated polio vaccine (sIPV) at a production cost of 0.25$ per dose, increasing thus vaccine availability for developing countries. In the meantime, preliminary data of the case-study are already available: https://goo.gl/VkxDM3
Notre CEO, Hugues Bultot explique la technologie innovative de UNIVERCELLS qui permettra de produire des vaccins plus accessibles et plus abordables dans un entretien Le Soir Economie https://goo.gl/QmSuhf"Nous ambitionnons de rentrer en bourse en 2021-2022 sur le Nasdaq. Cette date correspond à la maturité de notre activité de développement de plateforme technologique et à la constitution d’un portefeuille minimal de produits biologiques (vaccins, anticorps monoclonaux)", déclare Hugues Bultot.